John L Stock
Overview
Explore the profile of John L Stock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stock J, Coderre J, Simon J
Am J Primatol
. 2020 Jan;
23(3):201-206.
PMID: 31952403
Changes in parathyroid hormone and its second messenger cyclic AMP have been implicated in the pathogenesis of osteoporosis. Nonhuman primate models have been useful in the study of osteoporosis, but...
2.
Grady D, Cauley J, Stock J, Cox D, Mitlak B, Song J, et al.
Am J Med
. 2010 Apr;
123(5):469.e1-7.
PMID: 20399327
Objective: Raloxifene, a selective estrogen receptor modulator, reduces osteoporosis and invasive breast cancer risk but increases risk for venous thromboembolism and fatal stroke in women with or at high risk...
3.
Stock J, Mershon J, Schoenfeld M
Ann Intern Med
. 2008 Jun;
148(11):885.
PMID: 18519941
No abstract available.
4.
Ensrud K, Stock J, Barrett-Connor E, Grady D, Mosca L, Khaw K, et al.
J Bone Miner Res
. 2007 Sep;
23(1):112-20.
PMID: 17892376
Unlabelled: Using data from a randomized placebo-controlled trial of 10,101 postmenopausal women not selected on the basis of osteoporosis, we examined whether the effect of raloxifene treatment on fractures was...
5.
Recker R, Kendler D, Recknor C, Rooney T, Lewiecki E, Utian W, et al.
Bone
. 2006 Dec;
40(4):843-51.
PMID: 17182297
Unlabelled: The double-blind, randomized raloxifene alendronate comparison trial was the first study designed to compare two osteoporosis therapies head-to-head for fracture risk reduction. The original protocol planned to treat 3000...
6.
Qu Y, Wong M, Thiebaud D, Stock J
Curr Med Res Opin
. 2005 Dec;
21(12):1955-9.
PMID: 16368046
Objective: Raloxifene treatment (60 mg/day) significantly decreases the risk of new clinical vertebral fractures by 68% at 1 year compared with placebo. The objective of the present analysis is to...
7.
Siris E, Harris S, Eastell R, Zanchetta J, Goemaere S, Diez-Perez A, et al.
J Bone Miner Res
. 2005 Aug;
20(9):1514-24.
PMID: 16059623
Unlabelled: In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and raloxifene 60 mg/day. CORE...
8.
Adachi J, Adami S, Kulkarni P, Wong M, Stock J
J Clin Densitom
. 2005 Aug;
8(3):273-7.
PMID: 16055956
The ISCD recommends that bone mineral density (BMD) be monitored in patients undergoing antiresorptive therapy to identify patients with a significant BMD loss. This analysis compares the proportions of postmenopausal...
9.
Johnell O, Cauley J, Kulkarni P, Wong M, Stock J
J Fam Pract
. 2004 Oct;
53(10):789-96.
PMID: 15469774
Objective: We examined whether past use of hormone therapy influences the effects of raloxifene on the risk of new vertebral fracture, cardiovascular events, or breast cancer. Study Design: The Multiple...
10.
Silverman S, Delmas P, Kulkarni P, Stock J, Wong M, Plouffe Jr L
J Am Geriatr Soc
. 2004 Sep;
52(9):1543-8.
PMID: 15341559
Objectives: To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis. Design: A prospective, observational study of the placebo group in the double-blind,...